- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02350829
T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease
Quantification of Diffuse Myocardial Fibrosis in Children With Cardiomyopathy or Congenital Heart Disease by T1 Mapping Cardiac Magnetic Resonance
Diffuse fibrosis (or scarring) of the heart muscle is found in a variety of congenital heart diseases and in cardiomyopathies (heart muscle disease), and is considered a mediator of decreased cardiac function. The detection and quantification of diffuse myocardial fibrosis has recently become feasible non-invasively, using cardiac magnetic resonance (CMR), applying a new technique labeled T1 mapping. With this technique, the part of the heart tissue which is not made up of muscle cells (extracellular volume) can be quantified, as long as the individual's hematocrit (cellular volume in the blood) is known. The extracellular volume in the heart tissue is regarded as a quantifiable marker for the extent of diffuse myocardial fibrosis.
In the proposed study this new T1 mapping technique shall be applied in patients with different forms of congenital heart disease (n=130), cardiomyopathies (n=40) and in control subjects (n=30). The additional scan time due to participation in the study will be approximately 5-10 minutes, without changing the clinical protocol.
The main objective is to study the presence and extent of myocardial fibrosis by T1 mapping CMR in pediatric patients with congenital heart disease and cardiomyopathies, in comparison to cardiovascularly healthy controls.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A better understanding of the mechanisms by which the heart muscle fails in pediatric heart disease may result in novel therapies directed at preventing rather than treating ventricular failure. The most likely mediator candidate for cardiac demise in congenital heart disease as well as the cardiomyopathies is diffuse myocardial fibrosis and non-favorable chronic biventricular remodeling. As such, fibrosis may be a marker, if not a mediator, preceding the onset of actual echocardiographic and clinical deterioration, opening opportunities for more timely and targeted treatment. Chronic stressors of myocardial function (hypoxemia, abnormal afterload or preload) appear to promote fibrosis. In some groups of patients, a genetically upregulated collagen metabolism seems to play a role. In adult patients with dilated cardiomyopathy the extent of myocardial fibrosis is predictive of outcome.
With cardiac magnetic resonance imaging, the characterization of myocardial tissue is possible. Whereas standard late gadolinium enhancement (LGE) CMR can only identify patchy scars neighboring healthy tissue, quantification of diffuse myocardial fibrosis in the living has become feasible with the T1 mapping technique. Both techniques (T1 mapping and LGE) are based on the principle that MR contrast medium (gadolinium) is trapped in between collagen fibres and is retained in areas of fibrosis while it is quickly washed out of healthy myocardium. As gadolinium is a T1 shortening agent, the fibrosed tissue with its 'trapped' gadolinium has a shorter T1 time than healthy tissue. T1 mapping measures the T1 time constant, which has been shown to correlate with the degree of fibrosis. In a refined approach of this technique, which we will use, it is now possible to quantify the extracellular space (equivalent to the degree of fibrosis) by T1 mapping. This method has been validated against the current gold standard of surgical myocardial biopsy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Patients with cardiomyopathies (clinically established diagnosis of dilated or hypertrophic cardiomyopathy) / Patients with congenital heart disease (Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage) scheduled for an MR investigation including gadolinium (MRI contrast medium)
- Patients / guardians capable of giving informed consent
- Informed written consent / assent by the parents / legal guardians and patients where applicable
- Ability to undergo a MRI examination without anaesthesia. Children > 6 years are typically able to cooperate sufficiently.
- Control Patients: Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) including gadolinium without a history of cardiac disease
Exclusion Criteria:- Consent / assent refusal by guardian / patient
- General contraindications for a MRI examination such as non-MRI compatible metallic implants, claustrophobia.
- No contrast required for the clinical portion of the MRI
- Patients who require anaesthesia for MRI (typically < 6 years of age)
- Known renal failure or previous allergic reaction to gadolinium containing contrast agent
- Control subjects: history of cardiac problems, e.g. rhythm disorders, former myocarditis, active myositis or other inflammatory conditions except suspected or confirmed inflammatory bowel disease such as Crohn's disease or ulcerative colitis
- Known pregnancy or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cardiomyopathy
Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers |
Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
|
Active Comparator: Congenital Heart Disease
Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers |
Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
|
Active Comparator: Controls
Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
|
Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measuring degree of diffuse myocardial fibrosis
Time Frame: Once at the end of the visit
|
Participants will be followed for the duration of hospital visit, which is approximately 2 hours for the MRI part, and eventually longer, depending on possible other appointments on that day
|
Once at the end of the visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lars Grosse-Wortmann, MD, The Hospital for Sick Children
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000039963
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiomyopathy
-
University of AberdeenNHS GrampianCompletedTako-tsubo CardiomyopathyUnited Kingdom
-
Capricor Inc.National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsUnknownHeart Failure | Ischemic Cardiomyopathy | Nonischemic Cardiomyopathy | Dilated Cardiomyopathy (DCM)United States
-
University of California, IrvineWithdrawnDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Restrictive Cardiomyopathy | Mitochondrial Cardiomyopathy | Noncompaction CardiomyopathyUnited States
-
University Hospital HeidelbergCharite University, Berlin, Germany; Goethe University; University Medicine Greifswald and other collaboratorsRecruitingAmyloidosis | HCM - Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Inflammatory Cardiomyopathy | DCM - Dilated Cardiomyopathy | Non-ischemic Cardiomyopathy | HOCM - Hypertrophic Obstructive Cardiomyopathy | Left Ventricular Noncompaction CardiomyopathyGermany
-
Dennis M. McNamara, MD, MSNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPeripartum Cardiomyopathy, PostpartumUnited States
-
University Medical Center GroningenAstraZenecaCompletedHeart Failure | Cardiomyopathy, Familial | Phospholamban R14del CardiomyopathyNetherlands
-
German Heart InstituteDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)UnknownDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Arrhythmogenic Right Ventricular Cardiomyopathy | Restrictive Cardiomyopathy | Left Ventricular Noncompaction | Primary CardiomyopathyGermany
-
University of Cape TownMedtronicSuspendedDilated Cardiomyopathy | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathySouth Africa
-
Wayne State UniversityChildren's Hospital of Philadelphia; Washington University School of Medicine; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Restrictive CardiomyopathyUnited States, Canada
-
Hospital General Universitario Gregorio MarañonMinisterio de Sanidad, Servicios Sociales e IgualdadUnknownPrimary Idiopathic Dilated CardiomyopathySpain
Clinical Trials on Cardiac magnetic resonance sequence T1 mapping
-
Dr. Andreas KammerlanderUnknownHeart Failure | Coronary Disease | NAFLD | Valvular DiseaseAustria
-
Oxford University Hospitals NHS TrustCompletedAtrial FibrillationUnited Kingdom
-
Tianjin First Central HospitalUnknownDiabetic Cardiomyopathy | Simultaneous Pancreas-kidney TransplantationChina
-
University of MichiganNational Cancer Institute (NCI); SanofiRecruiting
-
University of MinnesotaRecruiting
-
IRCCS San RaffaeleCompletedLeft Ventricular Diastolic DysfunctionItaly
-
Assiut UniversityActive, not recruiting
-
Antonio EspositoMinistry of Health, ItalyUnknownMyocardial Inflammation | Myocarditis AcuteItaly
-
University of Turin, ItalyUniversity of Messina; Istituto Auxologico Italiano; Ministry of Health, Italy; A.O.U. Città della Salute e della Scienza - Molinette HospitalRecruiting
-
Alejandro Rodriguez Oviedo , MDTerminatedMyocardial Ischemia | Pneumonia, PneumococcalSpain